Isoferulic acid
Based on 3 publication(s) in Google Scholar
Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.91%
- No. CAS: 537-73-5
- Fòrmula: C10H10O4
- Peso molecular:194.19
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Isoferulic acid
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| B16-BL6 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| EA.hy 926 | EC50 |
29.3 μM
Compound: 3-OH-4-OCH3-cinnamic acid
|
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
|
10.1039/C4MD00022F |
| HeLa | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| HeLa | IC50 |
>=10 μM
Compound: isoferulic acid
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19278239] |
| HT-1080 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| Oocyte | IC50 |
13.5 μM
Compound: 4-O-Me-Caf-COOH
|
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
|
[PMID: 23682762] |
| RAW264.7 | IC50 |
>50 μM
Compound: 12
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
|
[PMID: 22079762] |
Isoferulic acid has IC50 values of 7.30, 4.58, 1.08, 8.84, 7.69, 1.57 and 13.33 μg/mL, respectively, for lipid peroxidation, DPPH and ABTS radical scavenging, reducing power on Fe3+ and Cu2+ ions, and hydroxyl and superoxide anion radical scavenging[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Isoferulic acid (0.25-1.0 mg/kg; oral administration; 4 days) has antiviral activity in mice infected with the influenza virus[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats weighing 200 to 250 g treated Streptozotocin (HY-13753) [2]
-
Dosage:0.5, 1, 3, 5 and 10 mg/kg
-
Administration:Intravenous injection; single dose
-
Result:Dose-dependently lowered plasma glucose concentrations and increased plasma plasma β-endorphin-like immunoreactivity in rats. This effect was abolished by pretreatment with α₁-adrenoceptor antagonists or opioid μ-receptor antagonists.
-
Animal Model:ICR female aged 4 weeks old mice (body weight, approximately 17 g) treated influenza virus[3]
-
Dosage:0.25, 0.5 and 1.0 mg/kg
-
Administration:Oral administration; 4 days
-
Result:Significantly improved survival rate and reduced body weight loss compared to the control group at dose of 0.5 mg/kg.
Had a slightly beneficial effect on survival rates at dose of 0.25 mg/kg, and had no effect at dose of 1 mg/kg.
Chemical Information
-
No. CAS 537-73-5
-
Appearance Solid
-
Peso molecular 194.19
-
Fòrmula C10H10O4
-
Color White to off-white
-
SMILES
O=C(O)/C=C/C1=CC=C(OC)C(O)=C1
-
Synonyms
3-Hydroxy-4-methoxycinnamic acid
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Chin Med
Therapeutic potential of Sheng-Xian-Tang in doxorubicin-induced chronic heart failure by regulation of phenylalanine metabolism disruption. [Abstract]2026 Jan 12;21(1):29. PMID: 41527105 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Iran J Pharm Res
Geranyl Acetate Attenuates Para-phenylenediamine-induced Cytotoxicity, DNA Damage, Apoptosis, and Inflammation in HaCaT Keratinocytes. [Abstract]2025 Oct 1;24(1):e164379. PMID: 41104235
Solvente y solubilidad
DMSO : 100 mg/mL (514.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (10.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (10.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Wang X, et al. Evaluation of antioxidant activity of isoferulic acid in vitro. Nat Prod Commun. 2011 Sep;6(9):1285-8. [Content Brief]
[2]. Liu IM, et al. Mediation of beta-endorphin by isoferulic acid to lower plasma glucose in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2003 Dec;307(3):1196-204. [Content Brief]
[3]. Sakai S, et al. Administration of isoferulic acid improved the survival rate of lethal influenza virus pneumonia in mice. Mediators Inflamm. 2001 Apr;10(2):93-6. [Content Brief]
[4]. Meeprom A, et al. Isoferulic acid, a new anti-glycation agent, inhibits fructose- and glucose-mediated protein glycation in vitro. Molecules. 2013 May 30;18(6):6439-54. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.1496 mL | 25.7480 mL | 51.4960 mL | 128.7399 mL |
| 5 mM | 1.0299 mL | 5.1496 mL | 10.2992 mL | 25.7480 mL | |
| 10 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL | 12.8740 mL | |
| 15 mM | 0.3433 mL | 1.7165 mL | 3.4331 mL | 8.5827 mL | |
| 20 mM | 0.2575 mL | 1.2874 mL | 2.5748 mL | 6.4370 mL | |
| 25 mM | 0.2060 mL | 1.0299 mL | 2.0598 mL | 5.1496 mL | |
| 30 mM | 0.1717 mL | 0.8583 mL | 1.7165 mL | 4.2913 mL | |
| 40 mM | 0.1287 mL | 0.6437 mL | 1.2874 mL | 3.2185 mL | |
| 50 mM | 0.1030 mL | 0.5150 mL | 1.0299 mL | 2.5748 mL | |
| 60 mM | 0.0858 mL | 0.4291 mL | 0.8583 mL | 2.1457 mL | |
| 80 mM | 0.0644 mL | 0.3218 mL | 0.6437 mL | 1.6092 mL | |
| 100 mM | 0.0515 mL | 0.2575 mL | 0.5150 mL | 1.2874 mL |